SMT201500213B - Alcune triazolopirazine, loro composizioni e metodi d'uso - Google Patents

Alcune triazolopirazine, loro composizioni e metodi d'uso

Info

Publication number
SMT201500213B
SMT201500213B SM201500213T SM201500213T SMT201500213B SM T201500213 B SMT201500213 B SM T201500213B SM 201500213 T SM201500213 T SM 201500213T SM 201500213 T SM201500213 T SM 201500213T SM T201500213 B SMT201500213 B SM T201500213B
Authority
SM
San Marino
Prior art keywords
triazolopirazine
compositions
methods
Prior art date
Application number
SM201500213T
Other languages
English (en)
Italian (it)
Inventor
Wei-Guo Su
Hong Jia
Guangxiu Dai
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44226181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201500213(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of SMT201500213B publication Critical patent/SMT201500213B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
SM201500213T 2009-12-31 2015-09-09 Alcune triazolopirazine, loro composizioni e metodi d'uso SMT201500213B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2009076321 2009-12-31
PCT/CN2010/080499 WO2011079804A1 (en) 2009-12-31 2010-12-30 Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor

Publications (1)

Publication Number Publication Date
SMT201500213B true SMT201500213B (it) 2015-10-30

Family

ID=44226181

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500213T SMT201500213B (it) 2009-12-31 2015-09-09 Alcune triazolopirazine, loro composizioni e metodi d'uso

Country Status (38)

Country Link
US (8) US8987269B2 (xx)
EP (5) EP2519524A4 (xx)
JP (5) JP5337313B2 (xx)
KR (3) KR101905350B1 (xx)
CN (3) CN106117248B (xx)
AU (2) AU2010338712B2 (xx)
BR (1) BR112012016129B1 (xx)
CA (1) CA2785749C (xx)
CL (1) CL2012001752A1 (xx)
CO (1) CO6612235A2 (xx)
CU (1) CU24167B1 (xx)
CY (2) CY1118250T1 (xx)
DK (3) DK2719699T3 (xx)
DO (1) DOP2012000188A (xx)
EA (2) EA025466B1 (xx)
EC (1) ECSP12012011A (xx)
ES (4) ES2726152T3 (xx)
GT (1) GT201200220A (xx)
HK (2) HK1194071A1 (xx)
HR (3) HRP20221090T1 (xx)
HU (3) HUE059696T2 (xx)
IL (2) IL220433B (xx)
LT (1) LT3795573T (xx)
ME (1) ME02211B (xx)
MX (1) MX336996B (xx)
MY (1) MY179933A (xx)
NI (1) NI201200118A (xx)
NZ (1) NZ601128A (xx)
PE (3) PE20160588A1 (xx)
PL (3) PL3511330T3 (xx)
PT (3) PT2719699E (xx)
RS (3) RS63612B1 (xx)
SG (1) SG181781A1 (xx)
SI (2) SI2719699T1 (xx)
SM (1) SMT201500213B (xx)
UA (1) UA107822C2 (xx)
WO (1) WO2011079804A1 (xx)
ZA (1) ZA201205730B (xx)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2719699E (pt) * 2009-12-31 2015-09-30 Hutchison Medipharma Ltd Certas triazolopirazinas, suas composições e seus métodos de utilização
EP2571878B1 (en) * 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
CN103030654A (zh) * 2011-10-09 2013-04-10 济南赛文医药技术有限公司 一种小分子c-Met蛋白激酶抑制剂
CN102516046A (zh) * 2011-11-22 2012-06-27 太仓市运通化工厂 一种2-溴丙醛的合成方法
MX359888B (es) * 2012-03-30 2018-10-15 Rhizen Pharmaceuticals Sa Novedosos compuestos de 3h-imidazo [4,5-b] piridina 3,5-disubstituida y 3h- [1,2,3] triazolo [4,5-b] piridina 3,5-disubstituida como moduladores de c-met proteina cinasas.
CA2776178A1 (en) * 2012-04-05 2013-10-05 Hydro-Quebec Ionic compounds
KR101745741B1 (ko) 2012-08-13 2017-06-12 한국화학연구원 신규한 트리아졸로 피라진 유도체 및 그의 용도
EP2944637B1 (en) 2013-01-11 2020-02-19 FUJIFILM Corporation Nitrogen-containing heterocylic compound or salt thereof
CA2901269C (en) 2013-03-06 2022-01-18 Astrazeneca Ab Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
CN103265468A (zh) * 2013-06-17 2013-08-28 连云港盛和生物科技有限公司 一种2,4-二甲基-3-吡咯甲酸乙酯的合成方法
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
MX368311B (es) * 2013-09-30 2019-09-27 Korea Res Inst Chemical Tech Nuevos derivados de triazolopirazina y usos de los mismos.
EP3087070B1 (en) * 2013-12-26 2017-11-08 Ignyta, Inc. Pyrazolo[1,5-a]pyridine derivatives and methods of their use
JP2016048495A (ja) * 2014-08-28 2016-04-07 京セラ株式会社 携帯端末、レコメンドプログラム、レコメンドシステムおよびレコメンド方法
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
CN109400613B (zh) * 2015-12-31 2021-05-07 上海医药集团股份有限公司 喹啉类化合物富马酸盐的晶型、制备方法、组合物与应用
GB201616116D0 (en) 2016-09-22 2016-11-09 Astrazeneca Ab Use of c-Met inhibitors to treat cancers harbouring MET mutations
KR20180092096A (ko) * 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
ES2933513T3 (es) 2017-03-01 2023-02-09 Achillion Pharmaceuticals Inc Compuestos macrocíclicos para el tratamiento de trastornos médicos
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
KR101924801B1 (ko) 2017-08-16 2018-12-04 한국원자력의학원 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
EP3847174A4 (en) 2018-09-06 2022-06-15 Achillion Pharmaceuticals, Inc. MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS
KR20210057777A (ko) * 2018-09-11 2021-05-21 아스트라제네카 아베 3-[(1S)-1-이미다조[1,2-a]피리딘-6-일에틸]-5-(1-메틸피라졸-4-일)트리아졸로[4,5-b]피라진 및 이의 다형체의 개선된 제조 방법
KR20210093855A (ko) 2018-09-25 2021-07-28 아칠리온 파르마세우티칼스 인코포레이티드 보체 인자 d 억제제의 형태체 형태
SG11202104460UA (en) * 2018-10-30 2021-05-28 Repare Therapeutics Inc Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
WO2020124060A1 (en) 2018-12-14 2020-06-18 Beta Pharma, Inc. Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof
AU2020317381A1 (en) * 2019-07-22 2022-02-10 Repare Therapeutics Inc. Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors
CN115362162A (zh) * 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
WO2021229605A1 (en) * 2020-05-14 2021-11-18 Dr. Reddy's Laboratories Limited Process for preparation of savolitinib and its intermediates
JP2023543990A (ja) * 2020-09-28 2023-10-19 コデクシス， インコーポレイテッド キラルアミンを合成するための操作された生体触媒および方法
US20240076285A1 (en) * 2020-12-16 2024-03-07 Shankar Venkatraman Compounds and compositions for treating conditions associated with sting activity
KR102659095B1 (ko) 2021-01-08 2024-04-19 에이비온 주식회사 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법
CN113278019A (zh) * 2021-05-31 2021-08-20 河南偶联生物科技有限公司 一种咪唑并[1,2-a]吡啶类化合物的合成方法
WO2023205722A1 (en) * 2022-04-20 2023-10-26 Engrail Therapeutics, Inc. Gabaa receptor modulator salts, particles, and uses thereof
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
WO2024026410A2 (en) * 2022-07-29 2024-02-01 Baylor College Of Medicine Neurotrophic receptor tyrosine kinase (ntrk) inhibitors and methods using same
CN115611802B (zh) * 2022-12-02 2023-03-14 北京迪泰医药科技有限公司 一种3-乙酰基-2-氯吡啶的合成方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP1615931A1 (en) 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazines and methods of making and using the same
US6979505B2 (en) * 2003-06-09 2005-12-27 Utc Fuel Cells, Llc Method and apparatus for removal of contaminants from a hydrogen processor feed stream, as in a fuel cell power plant
MXPA06000091A (es) * 2003-07-02 2006-04-07 Sugen Inc Arilmetiltriazolo e imidazopirazinas como inhibidores de c-met.
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
AU2004274403A1 (en) 2003-09-03 2005-03-31 Aventis Pharmaceuticals Inc. 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds
EP1781654A1 (en) 2004-07-27 2007-05-09 SGX Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
WO2006018735A2 (en) 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds
CN101119996A (zh) * 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 化学化合物
AU2006215394B2 (en) * 2005-02-16 2009-10-08 Astrazeneca Ab Chemical compounds
AU2006320580B2 (en) 2005-11-30 2011-06-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
BRPI0620292B1 (pt) 2005-12-21 2021-08-24 Janssen Pharmaceutica N. V. Compostos de triazolopiridazinas como moduladores da cinase, composição, uso, combinação e processo de preparo do referido composto
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
WO2007138472A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
JP2010500365A (ja) 2006-08-07 2010-01-07 インサイト・コーポレイション キナーゼ阻害剤としてのトリアゾロトリアジン
CA2663528A1 (en) 2006-09-18 2008-03-27 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of c-met and uses thereof
PL2081937T3 (pl) * 2006-10-23 2013-01-31 Sgx Pharmaceuticals Inc Triazolopirydazynowe modulatory kinaz białkowych
BRPI0717320A2 (pt) 2006-10-23 2013-10-22 Sgx Pharmaceuticals Inc Triazóis bicíclicos como moduladores de proteína cinase
MX2009005144A (es) 2006-11-22 2009-05-27 Incyte Corp Imidazotriazinas e imidazopirimidinas como inhibidores de cinasa.
CA2683398A1 (en) 2007-04-10 2008-10-16 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US8148369B2 (en) 2007-05-10 2012-04-03 Janssen Pharmaceutica Nv Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
BRPI0908504A2 (pt) 2008-02-28 2015-08-11 Novatis Ag Compostos derivados de 3-metil-imidazo[1,2-b]piridazina, uso dos mesmos e composição farmacêutica
EP2310389B1 (en) 2008-05-22 2012-01-04 Amgen Inc. Heterocycles as protein kinase inhibitors
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
EA201200260A1 (ru) * 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
EP2467383A1 (en) * 2009-08-20 2012-06-27 Novartis AG Heterocyclic oxime compounds
PT2719699E (pt) 2009-12-31 2015-09-30 Hutchison Medipharma Ltd Certas triazolopirazinas, suas composições e seus métodos de utilização
EP2571878B1 (en) 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases

Also Published As

Publication number Publication date
EP3795573B1 (en) 2022-07-06
ES2726152T3 (es) 2019-10-02
DOP2012000188A (es) 2012-12-31
IL239997A0 (en) 2015-08-31
KR101771299B1 (ko) 2017-08-24
US10946014B2 (en) 2021-03-16
RS54217B1 (en) 2015-12-31
ZA201205730B (en) 2016-01-27
JP2019108345A (ja) 2019-07-04
AU2015203480B2 (en) 2017-10-26
JP6486999B2 (ja) 2019-03-20
HUE052828T2 (hu) 2021-05-28
US11896592B2 (en) 2024-02-13
PL3511330T3 (pl) 2021-04-19
UA107822C2 (xx) 2015-02-25
US8507487B2 (en) 2013-08-13
NZ601128A (en) 2014-12-24
AU2015203480A1 (en) 2015-07-16
GT201200220A (es) 2014-12-22
AU2010338712B2 (en) 2015-04-02
HK1216880A1 (zh) 2016-12-09
CO6612235A2 (es) 2013-02-01
WO2011079804A1 (en) 2011-07-07
ES2927146T3 (es) 2022-11-02
SI2719699T1 (sl) 2015-12-31
KR20120125261A (ko) 2012-11-14
EP2719699B1 (en) 2015-07-08
AU2010338712A1 (en) 2012-07-12
EP3511330B1 (en) 2020-09-30
LT3795573T (lt) 2022-11-10
HUE059696T2 (hu) 2022-12-28
PL3795573T3 (pl) 2022-11-21
EA030141B1 (ru) 2018-06-29
CY1118250T1 (el) 2017-06-28
EP3795573A1 (en) 2021-03-24
KR20170098324A (ko) 2017-08-29
DK3795573T3 (da) 2022-09-19
EP2966075B1 (en) 2019-02-27
CN102906092B (zh) 2016-08-03
CY1123777T1 (el) 2022-03-24
PE20130375A1 (es) 2013-04-10
PT3795573T (pt) 2022-09-15
CU24167B1 (es) 2016-03-31
NI201200118A (es) 2013-01-24
PE20211094A1 (es) 2021-06-14
KR101905350B1 (ko) 2018-11-30
MY179933A (en) 2020-11-19
PT2719699E (pt) 2015-09-30
SG181781A1 (en) 2012-07-30
PE20160588A1 (es) 2016-07-09
ME02211B (me) 2016-02-20
CN106117248A (zh) 2016-11-16
ES2840454T3 (es) 2021-07-06
EP2966075A1 (en) 2016-01-13
BR112012016129A2 (pt) 2016-05-31
US20180263977A1 (en) 2018-09-20
EP2519524A4 (en) 2013-07-03
US10512645B2 (en) 2019-12-24
JP2018009004A (ja) 2018-01-18
HK1194071A1 (en) 2014-10-10
JP2013209418A (ja) 2013-10-10
EP3511330A1 (en) 2019-07-17
CU20120101A7 (es) 2012-10-15
IL220433B (en) 2018-01-31
US20210154192A1 (en) 2021-05-27
CN102906092A (zh) 2013-01-30
ECSP12012011A (es) 2012-10-30
EP2719699A1 (en) 2014-04-16
DK3511330T3 (da) 2020-12-21
CL2012001752A1 (es) 2013-01-25
CN106117248B (zh) 2019-01-22
KR101434766B1 (ko) 2014-08-26
EP2519524A1 (en) 2012-11-07
US20120245178A1 (en) 2012-09-27
CA2785749A1 (en) 2011-07-07
US8987269B2 (en) 2015-03-24
HRP20150952T1 (hr) 2015-10-09
JP2016155848A (ja) 2016-09-01
MX336996B (es) 2016-02-09
JP5337313B2 (ja) 2013-11-06
US20240139182A1 (en) 2024-05-02
IL239997A (en) 2017-11-30
CN106432225B (zh) 2019-02-19
CN106432225A (zh) 2017-02-22
DK2719699T3 (en) 2015-08-24
ES2546635T3 (es) 2015-09-25
HRP20221090T1 (hr) 2022-11-25
PL2719699T3 (pl) 2016-01-29
BR112012016129B1 (pt) 2020-11-03
EA201200951A1 (ru) 2013-09-30
US20120264739A1 (en) 2012-10-18
JP6194046B2 (ja) 2017-09-06
US20200179377A1 (en) 2020-06-11
US9956218B2 (en) 2018-05-01
JP2013516393A (ja) 2013-05-13
HRP20202017T1 (hr) 2021-02-19
KR20140059307A (ko) 2014-05-15
PT3511330T (pt) 2020-12-24
CA2785749C (en) 2017-11-28
SI3511330T1 (sl) 2021-01-29
JP6647434B2 (ja) 2020-02-14
RS63612B1 (sr) 2022-10-31
MX2012007756A (es) 2012-11-06
RS61281B1 (sr) 2021-02-26
US20150368271A1 (en) 2015-12-24
EA201691461A1 (ru) 2017-01-30
US20170027934A1 (en) 2017-02-02
EA025466B1 (ru) 2016-12-30
HUE025504T2 (en) 2016-02-29

Similar Documents

Publication Publication Date Title
SMT201500213B (it) Alcune triazolopirazine, loro composizioni e metodi d'uso
SMT201600226B (it) Alcune amminopirimidine, loro composizioni e metodi per il loro uso
SMT201600388B (it) Ligandi leganti opsina, composizioni e metodi d'uso
SMT201400055B (it) Composti di tioacetato, composizioni e metodi d'uso
SMT201500206B (it) Composti spiro-ossindolici e loro uso come agenti terapeutici
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI1014854A2 (pt) "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados"
SMT201400181B (it) Composizioni per vasocostrizione e metodi d'uso
BRPI0818003A2 (pt) inibidores de csf-1r, composições e métodos de uso
BRPI1005292A2 (pt) composição de decapagem e uso da composição
BRPI0911688A2 (pt) "compostos de pirimidina, composições e métodos de uso"
BRPI0913086A2 (pt) Composições antimicrobianas e métodos de uso
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
BRPI0816350A2 (pt) Composições orais, produtos e métodos de uso
BRPI0920263A2 (pt) composto, uso do composto, composição, e, método
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BR112012000735A2 (pt) "métodos, kits e conjuntos de compostos"
SMT201500218B (it) Composti aril-fenil-solfonammido-cicloalchile e loro uso
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0812159A2 (pt) inibidores de csf-1r, composições e métodos de uso
BRPI1007494A2 (pt) composto e uso do mesmo
FI20096058A0 (fi) Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
BRPI1005670A8 (pt) composições adjuvantes e processos de uso.
BRPI1008215A2 (pt) "composição azeotrópica"